CMA

FTC

Pharma

Pfizer, Seagen kick off FTC review of $43B merger

Pfizer's $43 billion Seagen deal is now up for its high-stakes review at the FTC.

Angus Liu May 15, 2023 10:41am

Fine

In appeal, Advanz calls UK fine 'manifestly wrong'

Sep 27, 2022 3:48pm

Pfizer

Pfizer, Flynn Pharma slapped with £70 million antitrust fine

Jul 21, 2022 10:56am